Exciting Updates from Insilico Medicine’s Pharma.ai Webinar: On-Demand Recording Available!
Highlights from the Summer 2025 Platform Updates
Key Features Unveiled:
- Generative Biologics: Advanced antibody design capabilities using AI.
- Chemistry42: Enhanced chemistry model for improved performance.
- PandaOmics: New tools for comprehensive omics analysis.
- DORA: Next-gen AI research assistant.
- PreciousGPT: Innovations in aging research.
For the full recap and insights, access the on-demand recording now!
Unlocking the Future of Drug Discovery: Highlights from Insilico Medicine’s Summer Updates Webinar
For those who missed it, the on-demand recording of Insilico Medicine’s latest Pharma.ai summer updates webinar is now available. You can access it here. This event was part of Insilico’s quarterly platform launch series and showcased exciting advancements in generative AI-driven drug discovery.
A Gathering of Innovators
The webinar attracted over 250 attendees from more than 45 countries, including researchers, educators, and pharmaceutical leaders. This diverse audience emphasized the global interest in transformative AI technology for drug discovery.
Key Highlights from the Webinar
1. Generative Biologics
Insilico announced a groundbreaking platform for biologics generation. This diffusion-based model allows for the customization of antibody scaffolds and sequences. Users can import the protein PDB code of interest directly, and the platform pre-processes the file to display detailed non-covalent interactions, enhancing the design process.
2. Chemistry42 Version 2.0
The enhanced architecture of Chemistry42 significantly boosts scalability and efficiency. The new version supports a range of target types, allowing researchers to visualize and download molecular dynamics, further revolutionizing the way researchers interact with chemistry data.
3. PandaOmics
PandaOmics continues to evolve, offering comprehensive omics analysis tools. The latest updates allow users to perform multi-entry data analysis and create customized meta-analyses. Enhanced security features like Virtual Private Cloud (VPC) and Single Sign-On (SSO) ensure data integrity and accessibility.
4. DORA: Advanced Research Assistant
Insilico is set to release DORA, an AI-driven research assistant designed to streamline biomedical document production. The open-source community will benefit from various deployment options, showcasing Insilico’s commitment to collaboration and knowledge sharing.
5. PreciousGPT: Multimodal Transformers
This new feature offers researchers access to aging clocks from prestigious institutions, enabling investigations into the aging process in fibrotic diseases. The integration of such tools reflects Insilico’s dedication to pushing the boundaries of biomedical research.
A Legacy of Innovation
Since its establishment in 2014, Insilico Medicine has become a leader in AI-driven drug discovery. The company aims to tackle unmet medical needs in various fields, including oncology, immunology, and metabolic disorders, through its Pharma.AI platform. Having published over 200 peer-reviewed papers and obtaining more than 600 patents, Insilico continues to lay the groundwork for the future of drug discovery.
Join the Movement
For those eager to learn more about Insilico Medicine’s innovative efforts in drug discovery, I encourage you to watch the on-demand webinar. Stay informed and be part of this exciting journey toward revolutionary healthcare solutions.
For more information, visit Insilico Medicine.
Credit: Insilico Medicine